Abstract 1662: Preclinical studies of RP04340: an orally available and potent PROTAC compound targeting KRAS G12C/D/V mutant tumors

克拉斯 药理学 医学 突变体 癌症研究 癌症 化学 内科学 生物化学 结直肠癌 基因
作者
Xiang Ji,Chao Deng,Gang Wu,Qiguo Zhang,Xiaolin He,Yanpeng Wu,Bing Zong,Xiaojin Xu,Chao Liang,Beibei Wang,Yu‐Wei Zhang,Qingyao Hu,Huanping Li,Bing Bai,Lin Wang,Jinchao Ai,Leduo Zhang,Honggui Zhou,Shihao Sun,Yijie Wang
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_1): 1662-1662
标识
DOI:10.1158/1538-7445.am2025-1662
摘要

Mutations in the RAS oncogene are highly prevalent in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and lung adenocarcinoma (LUAD), with codon 12 of the KRAS gene being the most frequently altered site. Substitutions of glycine at codon 12 to cysteine (G12C), glutamate (G12D), or valine (G12V) occur in 66.3%, 23.7%, and 24.4% of PDAC, CRC, and LUAD patients, respectively. While recently approved drugs targeting KRAS G12C mutation have shown clinical benefit, there remains a significant unmet need for therapies addressing the highly prevalent G12D and G12V mutations. Proteolysis-targeting chimeras (PROTACs) represent a novel therapeutic strategy for the targeted degradation of oncogenic proteins, potentially offering superior efficacy and mitigating resistance. In this study, we present RP04340, a potent and orally bioavailable PROTAC compound that selectively degrades KRAS G12C/D/V proteins and demonstrates robust anti-tumor activity. RP04340 induced significant degradation of KRAS G12C, KRAS G12D, and KRAS G12V proteins in cell lines Miapaca-2, PK-59, and NCI-H727, respectively, with a 50% degradation concentration (DC50) in the low nanomolar range. Within 12 hours of treatment, RP04340 reduced KRAS G12C/D/V protein levels by over 80% and effectively suppressed downstream signaling pathways, including pERK and DUSP6. Additionally, RP04340 inhibited cell proliferation in multiple KRAS G12C/D/V mutant cell lines, surpassing the anti-tumor efficacy of its enzymatic inhibitor warhead. In vivo studies using mouse xenograft models (Miapaca-2, PK-59, and NCI-H727) demonstrated significant tumor growth inhibition following daily oral administration of RP04340 at doses of 25, 50, and 100 mg/kg, with a clear dose-response relationship. Pharmacokinetic analyses revealed that RP04340 accumulated preferentially in tumor tissues, achieving high intratumoral concentrations with repeated dosing. Furthermore, tissue distribution studies in mouse showed significant accumulation of RP04340 in the lungs and pancreas after 15 days of consecutive dosing, supporting its suitability for treating cancers in these organs. In conclusion, RP04340, a PROTAC compound with compelling preclinical efficacy and favorable pharmacokinetic properties, represents a promising therapeutic candidate for KRAS G12C/D/V-driven cancers. Citation Format: Xiang Ji, Chao Deng, Gang Wu, Qiguo Zhang, Xiaolin He, Yanpeng Wu, Bing Zong, Xiaojin Xu, Chao Liang, Beibei Wang, Yuwei Zhang, Qingyao Hu, Huanping Li, Bing Bai, Lin Wang, Jinchao Ai, Leduo Zhang, Honggui Zhou, Shihao Sun, Yijie Wang, Youhong Wang, Xianqi Kong, Dawei Chen, Tianlun Zhou, Jiasheng Lu. Preclinical studies of RP04340: an orally available and potent PROTAC compound targeting KRAS G12C/D/V mutant tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1662.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
萌~Lucky完成签到,获得积分10
1秒前
2秒前
科研通AI6.3的应助被鬼先生采纳,获得10
2秒前
初景的应助被geold采纳,获得20
3秒前
汉堡包的应助被stanfordlee采纳,获得10
4秒前
kuku发布了新的文献求助10
4秒前
王悦靓发布了新的文献求助10
4秒前
无私尔风完成签到,获得积分10
4秒前
平静的人完成签到 ,获得积分10
4秒前
孙大伟完成签到,获得积分20
4秒前
吾吾发布了新的文献求助10
4秒前
5秒前
5秒前
mm完成签到,获得积分10
5秒前
popooo完成签到,获得积分10
5秒前
stayu完成签到 ,获得积分10
5秒前
糖醋花孙米完成签到,获得积分10
5秒前
科研通AI2S的应助被lihao采纳,获得10
6秒前
2000皁空完成签到,获得积分10
6秒前
小连完成签到,获得积分10
6秒前
厉奕欣发布了新的文献求助10
6秒前
7秒前
zzz发布了新的文献求助10
7秒前
happy_everyday完成签到,获得积分10
7秒前
7秒前
科目三的应助被风吹麦浪采纳,获得10
7秒前
7秒前
Something完成签到,获得积分10
8秒前
8秒前
dxftx发布了新的文献求助10
8秒前
手可摘棉花完成签到,获得积分10
9秒前
9秒前
9秒前
Merry8558完成签到,获得积分10
11秒前
11秒前
dengzx08完成签到,获得积分10
11秒前
CS发布了新的文献求助10
11秒前
陈九思完成签到,获得积分10
11秒前
刘大宝完成签到,获得积分10
11秒前
rxl发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315